Dr. Suresh V. Kuchipudi's educational journey began in India with a bachelor's degree in veterinary science from Acharya N.G. Ranga Agricultural University, followed by a master's degree in microbiology from Tamil Nadu Veterinary and Animal Sciences University. Driven by his passion for virology, he pursued a doctorate from the University of Glasgow. To further enhance his expertise, he obtained a postgraduate certificate in higher education from the University of Nottingham and a master's degree in business administration from Penn State Smeal College of Business. In addition, with prior experience as a veterinary clinician and diplomate of the American College of Veterinary Microbiologists, he brings extensive knowledge and expertise in clinical virology and immunology.
Prior to joining the University of Pittsburgh, Dr. Kuchipudi held various academic and clinical positions. He served as the Dorothy Foehr Huck and J. Lloyd Huck Chair Professor in Emerging Infectious Diseases at the Penn State Huck Institutes of the Life Sciences and acted as the interim Director of the Penn State Animal Diagnostic Laboratory. Additionally, he worked as an assistant professor of molecular virology at the University of Nottingham and as an assistant professor at Sri Venkateswara Veterinary University in Tirupathi, India.
At the core of Dr. Kuchipudi's expertise lies his research focus on emerging and zoonotic viruses and their profound impact on global health. He investigates the complex interactions between pathogens and their hosts using a multi-disciplinary approach. The overall goal of his research is to unravel the factors that govern zoonotic virus transmission and adaptation. His research encompasses basic and translational aspects, including developing innovative diagnostics, vaccines, and therapeutics to combat these viruses and improve global health outcomes.
Dr. Kuchipudi's extensive experience is marked by his embrace of innovation and ability to forge effective partnerships. His team is actively involved in pioneering an oncolytic viral therapy for treating human and animal cancers. He has played a pivotal role in establishing several impactful global health collaborations, fostering international cooperation and knowledge exchange. Furthermore, in response to the challenges posed by the COVID-19 pandemic, he made significant contributions by planning and establishing a Clinical Laboratory Improvement Amendments (CLIA) lab for on-campus diagnostic testing at Penn State, showcasing his leadership and dedication to public health.
Dr. Kuchipudi's research findings have received widespread recognition, drawing attention from numerous media outlets and popular press publications. His expertise has earned him several competitive research grants and awards, including the Research Innovator of the Year award from Penn State in 2022. Committed to advancing education, Dr. Kuchipudi has extensive experience in teaching, curriculum design, and mentoring graduate students. He established the veterinary microbiology residency program at Penn State, nurturing the next generation of experts in the field. Dr. Kuchipudi serves as an editorial board member for several prestigious journals in the field, further contributing to the dissemination of knowledge and the advancement of scientific research.
2021: Master of Business Administration (MBA), Penn State Smeal College of Business, Concentration: Corporate innovation and entrepreneurship.
2018: Diplomate of American College of Veterinary Microbiologists (DACVM) - Immunology
2014: Diplomate ACVM-Virology
2012: Fellowship of Higher Education Academy (FHEA), UK
2012: Postgraduate Certificate in Higher Education (PGCHE), University of Nottingham, UK.
2010: Ph.D. in Virology, Institute of Comparative Medicine, College of Veterinary Medicine, University of Glasgow, Glasgow UK, 2010.
1999: Master of Veterinary Science (M.V.Sc) in microbiology- Tamil Nadu Veterinary and Animal Sciences University, Chennai, India, 1999.
1996: Bachelor of Veterinary Science and Animal Husbandry (BVSc &A.H-equivalent to DVM), Acharya N.G. Ranga Agricultural University, Hyderabad, India, 1996.
Li LX, Nissly RH, Swaminathan A, Bird IM, Boyle NR, Nair MS, Greenawalt DI, Gontu A, Cavener VS, Sornberger T, Freihaut JD, Kuchipudi SV*, Bahnfleth WP*. Inactivation of HCoV-NL63 and SARS-CoV-2 in aqueous solution by 254 nm UV-C. J Photochem Photobiol B. 2023 Jul 5;245:112755. doi: 10.1016/j.jphotobiol.2023.112755. Epub ahead of print. PMID: 37423001.
Kuchipudi SV*, Tan C, van Dorp L, Lichtveld M, Pickering B, Bowman J, Mubareka S, Balloux F. Coordinated surveillance is essential to monitor and mitigate the evolutionary impacts of SARS-CoV-2 spillover and circulation in animal hosts. Nat Ecol Evol. 2023 May 25. doi: 10.1038/s41559-023-02082-0. Epub ahead of print. Erratum in: Nat Ecol Evol. 2023 Jun 21;: PMID: 37231305.
Vishweshwaraiah YL, Hnath B, Rackley B, Wang J, Gontu A, Chandler M, Afonin KA, Kuchipudi SV, Christensen N, Yennawar NH, Dokholyan NV. Adaptation-proof SARS-CoV-2 vaccine design. Adv Funct Mater. 2022 Dec 2;32(49):2206055. doi: 10.1002/adfm.202206055. Epub 2022 Oct 3. PMID: 36590650; PMCID: PMC9799234.
Tan CCS, Lam SD, Richard D, Owen CJ, Berchtold D, Orengo C, Nair MS, Kuchipudi SV, Kapur V, van Dorp L, Balloux F. Transmission of SARS-CoV-2 from humans to animals and potential host adaptation. Nat Commun. 2022 May 27;13(1):2988. doi: 10.1038/s41467-022-30698-6. PMID: 35624123; PMCID: PMC9142586.
Kuchipudi SV*, Surendran-Nair M, Ruden RM, Yon M, Nissly RH, Vandegrift KJ, Nelli RK, Li L, Jayarao BM, Maranas CD, Levine N, Willgert K, Conlan AJK, Olsen RJ, Davis JJ, Musser JM, Hudson PJ, Kapur V. Multiple spillovers from humans and onward transmission of SARS-CoV-2 in white-tailed deer. Proc Natl Acad Sci U S A. 2022 Feb 8;119(6):e2121644119. doi: 10.1073/pnas.2121644119. PMID: 35078920; PMCID: PMC8833191.
Chen C, Boorla VS, Banerjee D, Chowdhury R, Cavener VS, Nissly RH, Gontu A, Boyle NR, Vandegrift K, Nair MS, Kuchipudi SV*, Maranas CD. Computational prediction of the effect of amino acid changes on the binding affinity between SARS-CoV-2 spike RBD and human ACE2. Proc Natl Acad Sci U S A. 2021 Oct 19;118(42):e2106480118. doi: 10.1073/pnas.2106480118. PMID: 34588290; PMCID: PMC8594574.
Gontu A, Srinivasan S, Salazar E, Nair MS, Nissly RH, Greenawalt D, Bird IM, Herzog CM, Ferrari MJ, Poojary I, Katani R, Lindner SE, Minns AM, Rossi R, Christensen PA, Castillo B, Chen J, Eagar TN, Yi X, Zhao P, Leveque C, Olsen RJ, Bernard DW, Gollihar J, Kuchipudi SV*, Musser JM, Kapur V. Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy. Commun Biol. 2021 Feb 24;4(1):267. doi: 10.1038/s42003-021-01813-y. PMID: 33627795; PMCID: PMC7904946.
* Corresponding author